Advertisement

Topics

Impax Laboratories (IPXL) Given a $35.00 Price Target by Cantor Fitzgerald Analysts

17:43 EST 16 Dec 2017 | Topix
Related Biotechnology, Pharmaceutical and Healthcare News

The brokerage currently has a buy rating on the specialty pharmaceutical company's stock. Other research analysts have also recently issued reports about the company.

Original Article: Impax Laboratories (IPXL) Given a $35.00 Price Target by Cantor Fitzgerald Analysts

NEXT ARTICLE

More From BioPortfolio on "Impax Laboratories (IPXL) Given a $35.00 Price Target by Cantor Fitzgerald Analysts"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.